

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

TOBRAMYCIN INHALED

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TOBRAMYCIN	BETHKIS,		16122	GPI-14	
	TOBRAMYCIN			(07000070002530)	
TOBRAMYCIN IN 0.225%	TOBI		61551	GPI-14	
NACL	TOBRAMYCIN			(07000070002520)	
TOBRAMYCIN	TOBI		30025	GPI-14	
	PODHALER		34461	(07000070000120)	
TOBRAMYCIN/NEBULIZER	KITABIS PAK		37569	GPI-14	
				(07000070002520)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of cystic fibrosis?

If yes, continue to #2. If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

2. Is the patient 6 years of age or older?

If yes, continue to #3. If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient have a lung infection with a gram-negative species (such as *Pseudomonas aeruginosa*; *Staphylococcus aureus* is not a gram-negative species)?

If yes, approve the requested agent for 12 months by GPID or GPI-14 as follows:

• Tobi: #280mL (#56 of 5mL ampules) per 28 days (fill count = 6)

Tobi Podhaler: #224 capsules per 28 days (fill count = 6)

Bethkis: #224mL (#56 of 4mL ampules) per 28 days (fill count = 6)

Kitabis Pak: #280mL per 28 days (fill count = 6)

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE

Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/22/2020 Page 1 of 2



TOBRAMYCIN INHALED

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TOBRAMYCIN INHALED** (Bethkis, Tobi, Tobi Podhaler, Kitabis Pak) requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
- B. You are 6 years of age or older
- C. You have a lung infection with a gram-negative species (type of bacteria that does not stain a purple color)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tobi, Bethkis or Kitabis.

REFERENCES

- Tobi [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2018.
- Tobi Podhaler [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2018.
- Bethkis [Prescribing Information]. Woodstock, IL: Chiesi USA, Inc.; December 2019.
- Kitabis Pak [Prescribing Information]. Midothian, VA: PARI Respiratory Equipment, Inc.; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 05/12

Commercial Effective: 09/25/20 Client Approval: 07/20 P&T Approval: 10/20

Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/22/2020 Page 2 of 2